Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 9/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29344290 | 0.88 | METAP2 (0.38) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL31527551 | 0.84 | METAP2 (0.43) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL30959317 | 0.79 | IDO1 (0.38) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL20974448 | 0.76 | METAP2 (0.45) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL29937247 | 0.76 | METAP2 (0.45) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL21196238 | 0.75 | IDO1 (0.48) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL19948646 | 0.73 | IDO1 (0.47) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL30410207 | 0.73 | IDO1 (0.47) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL23043392 | 0.72 | TRPA1 (0.45) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL30959994 | 0.72 | TRPA1 (0.45) | METAP2CYP1A2PTPN6IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076523-A1 | RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | METAP2 3168/4885CYP1A2 4576/4885PTPN6 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.